Preliminary evidence of sustained expression of angiopoietin‐2 during monocyte differentiation in chronic hepatitis C

Rodríguez-Muñoz, Y.; Martı́n-Vı́lchez, Samuel; López‐Rodríguez, Rosario; Hernández-Bartolomé, Ángel; Garcı́a-Buey, Luisa; Borque, M.J.; Moreno–Otero, Ricardo; Sanz-Cameno, Paloma

doi:10.1111/liv.12125

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Implicit in this generalized endothelial dysfunction may be an imbalance of angiogenic and anti-angiogenic factors, with decreased levels of pro-angiogenic factors such as VEGF and Ang-2. [ 25 , 26 ] Previous studies have reported elevated circulatory Ang-2 and VEGF levels in patients with hepatitis C [ 27 , 28 ]. This could be a possible pathway for the findings of a decreased preeclampsia risk in our study.…”

Section: Discussionmentioning

confidence: 99%

Pregnancy outcome in more than 5000 births to women with viral hepatitis: a population-based cohort study in Sweden

et al. 2017

View full text Add to dashboard Cite

Previous studies have shown inconsistent results with respect to hepatitis B (HBV), hepatitis C (HCV) and pregnancy outcome. The aim of this study was to investigate pregnancy outcome in women with HBV or HCV. In a nationwide cohort of births between 2001 and 2011 we investigated the risks of adverse pregnancy outcomes in 2990 births to women with HBV and 2056 births to women with HCV using data from Swedish healthcare registries. Births to women without HBV (n = 1090 979), and births without HCV (n = 1091 913) served as population controls. Crude and adjusted relative risks (aRR) were calculated using Poisson regression analysis. Women with HCV were more likely to smoke (46.7 vs. 8.0%) and to have alcohol dependence (18.9 vs. 1.3%) compared with population controls. Most women with HBV were born in non-Nordic countries (91.9%). Maternal HCV was associated with a decreased risk of preeclampsia (aRR: 0.39, 95% CI: 0.24–0.64), but an increased risk of preterm birth (aRR: 1.32, 95% CI: 1.08–1.60) and late neonatal death (7–27 days: aRR: 3.79, 95% CI: 1.07–13.39) Preterm birth were also more common in mothers with HBV, aRR: 1.21 (95% CI: 1.02–1.45). Both HBV and HCV are risk factors for preterm birth, while HCV seems to be associated with a decreased risk for preeclampsia. Future studies should corroborate these findings.Electronic supplementary materialThe online version of this article (doi:10.1007/s10654-017-0261-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Pregnancy outcome in more than 5000 births to women with viral hepatitis: a population-based cohort study in Sweden

et al. 2017

View full text Add to dashboard Cite

show abstract

New venues for the treatment of hepatitis: pharmacological or genetical interventions of macrophage polarization by targeting Ang/Tie‐2 axis

Zhou

Lin

Huang

et al. 2013

Liver International

View full text Add to dashboard Cite

Hepatitis C virus-mediated angiogenesis: Molecular mechanisms and therapeutic strategies

Hassan

Selimović

El-Khattouti

et al. 2014

WJG

View full text Add to dashboard Cite

Angiogenesis is an essential process for organ growth and repair. Thus, an imbalance in this process can lead to several diseases including malignancy. Angiogenesis is a critical step in vascular remodeling, tissue damage and wound healing besides being required for invasive tumor growth and metastasis. Because angiogenesis sets an important point in the control of tumor progression, its inhibition is considered a valuable therapeutic approach for tumor treatment. Chronic liver disease including hepatitis C virus (HCV) infection is one of the main cause for the development of hepatic angiogenesis and thereby plays a critical role in the modulation of hepatic angiogenesis that finally leads to hepatocellular carcinoma progression and invasion. Thus, understanding of the molecular mechanisms of HCV-mediated hepatic angiogenesis will help design a therapeutic protocol for the intervention of HCV-mediated angiogenesis and subsequently its outcome. In this review, we will focus on the molecular mechanisms of HCV-mediated hepatic angiogenesis and the related signaling pathways that can be target for current and under development therapeutic approaches.

show abstract

Preliminary evidence of sustained expression of angiopoietin‐2 during monocyte differentiation in chronic hepatitis C

Cited by 3 publications

References 35 publications

Pregnancy outcome in more than 5000 births to women with viral hepatitis: a population-based cohort study in Sweden

Pregnancy outcome in more than 5000 births to women with viral hepatitis: a population-based cohort study in Sweden

New venues for the treatment of hepatitis: pharmacological or genetical interventions of macrophage polarization by targeting Ang/Tie‐2 axis

Hepatitis C virus-mediated angiogenesis: Molecular mechanisms and therapeutic strategies

Contact Info

Product

Resources

About